Halia Therapeutics Announces Positive Phase 1 Clinical Trial Results for HT-6184 at the 5th Inflammasome Therapeutics Summit
LEHI, Utah, Nov. 29, 2023 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation, today announced positive results following the successful...
David Bearss is featured in Biosphere Magazine
David Bearss’ passion for drug discovery has guided his noteworthy career as a dynamic leader who integrates scientific and business interests to deliver new medicines to patients. That passion is still evident today as he gives back to the industry he loves, making a difference with bold initiatives to improve health and change the face of Utah’s life sciences ecosystem.
Halia’s new lab is featured in the Provo Daily Herald
Halia Therapeutics has a new lab in Lehi and believes it is on the forefront of research to target chronic inflammation to treat neurodegeneration and inflammatory diseases.
Halia Therapeutics Grand Opening Reported by FOX 13 KSTU August 23, 2023
Thanks to Salt Lake City’s FOX 13 News for attending and reporting on Halia Therapeutics’ grand opening. This report aired August 23, 2013.
BioTuesdays.com – Halia targeting chronic inflammation to keep people healthier, living longer
Closely-held Halia Therapeutics is developing a broad pipeline of novel therapies that are essential mediators of immune cell signaling with the potential to improve the lives of patients with inflammatory disorders and neurological diseases.
Halia Completes Phase I Enrollment for Lead Program – BioWorld: In the Clinic for August 8th, 2023
Read the entire article at: www.bioworld.com/articles/699721-in-the-clinic-for-aug-8-2023
Dr. David Bearss Discusses Chronic Inflammation and Disease on the First In Human Podcast
https://podcasts.apple.com/us/podcast/episode-37-david-bearss-ph-d-president-and-ceo-of/id1648796570?i=1000616814121 David Bearss, President and CEO of Halia Therapeutics, and Todd Kays, Vice President of Dermatology at Vile Health Technologies, discuss the connection...
Dr. David Bearss Interview With Neal Howard of Health Professional Radio
Halia Therapeutics – Eliminating Chronic Inflammation by Targeting the NLRP3 Inflammasome Dr. David Bearss, PhD, President and CEO at Halia Therapeutics, a clinical-stage biopharma company developing novel therapies to improve the lives of patients with inflammatory...
Dr. David J. Bearss Recipient of 2023 Governor’s Medal of Science Award
We are proud to announce that Halia CEO David Bearss Ph.D. will be awarded the 2023 Governor’s Medal for Science and Technology on May 2nd at the One Utah Summit. https://business.utah.gov/news/recipients-of-the-2023-utah-governors-science-medals-announced/
Targeting a Regulator of Inflammation to Treat Alzheimer’s Disease
The Bio Report David Bearss Ph.D., president and CEO of Halia Therapeutics, Inc., discusses with Daniel Levine the NLRP3 inflammasome, the role it plays in Alzheimer’s disease and other neurologic conditions, and the case for the company's therapeutic approach....
Empowered Patient Podcast episode featuring David J. Bearss
Empowered Patient Podcast David Bearss the Co-Founder, CEO and President of Halia Therapeutics, points out that despite traditional thinking, chronic inflammation is not just an unresolved acute inflammatory response. It has been discovered that a different pathway...
Biopharma Execs Adopt Creative Mindset at BIO CEO
BioSpace Biopharma Execs Adopt Creative Mindset at BIO CEO https://www.biospace.com/article/biopharma-execs-adopt-creative-mindset-at-bio-ceo-/
Up and down the ladder: The latest comings and goings
STAT Up and down the ladder: The latest comings and goings https://www.statnews.com/pharmalot/2023/01/20/pharma-jobs-dianthus-catalent-cytovance/
Chutes & Ladders—David Kessler resigns from the Biden admin…unofficial end of Operation Warp Speed
Fierce Biotech Chutes & Ladders—David Kessler resigns from the Biden admin, marking the unofficial end of Operation Warp Speed https://www.fiercebiotech.com/biotech/chutes-ladders-david-kessler-resigns-biden-admin-marking-unofficial-end-operation-warp
‘Perfect time’: SIGA’s CEO on retirement; Juvenescence woos GSK vet to lead anti-aging play
Endpoints News 'Perfect time': SIGA's CEO on retirement; Juvenescence woos GSK vet to lead anti-aging play https://endpts.com/biopharma-jobs-report-perfect-time-sigas-ceo-on-retirement-juvenescence-woos-gsk-vet-to-lead-anti-aging-play/
Amgen’s Margit Janát-Amsbury named Halia CMO
The Pharma Letter Amgen’s Margit Janát-Amsbury named Halia CMO https://www.thepharmaletter.com/article/amgen-s-margit-janat-amsbury-named-halia-cmo
Appointments and advancements for Jan. 19, 2023
BioWorld Appointments and advancements for Jan. 19, 2023 https://www.bioworld.com/articles/693419-appointments-and-advancements-for-jan-19-2023?v=preview
Biotech CFOs sharpen financing tactics for lean times
CFO DIVE Biotech CFOs sharpen financing tactics for lean times https://www.cfodive.com/news/3-biotech-cfos-finding-financing-lean-times/640301/
BioUtah Announces Halia CEO David Bearss Ph.D. as their 2022 Entrepreneur of the Year Award Winner
David J. Bearss, Ph.D., Co-Founder, and CEO of Salt Lake City-based Halia Therapeutics, for his limitless and inspiring entrepreneurial spirit, mentorship, and achievements that are transforming therapeutics, spawning discovery, seeding startups, and strengthening...
Contact Us
Corporate Headquarters
3900 N. Traverse Mountain Blvd., Suite 100
Lehi, Utah 84043
United States
info@haliatx.com | +1 (385) 355-4315